| Sipuleucel-T immunotherapy for castration-resistant prostate cancer PW Kantoff, CS Higano, ND Shore, ER Berger, EJ Small, DF Penson, ... New England Journal of Medicine 363 (5), 411-422, 2010 | 4554 | 2010 |
| Gene expression correlates of clinical prostate cancer behavior D Singh, PG Febbo, K Ross, DG Jackson, J Manola, C Ladd, P Tamayo, ... Cancer cell 1 (2), 203-209, 2002 | 2566 | 2002 |
| Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo OC Farokhzad, J Cheng, BA Teply, I Sherifi, S Jon, PW Kantoff, JP Richie, ... Proceedings of the National Academy of Sciences 103 (16), 6315-6320, 2006 | 1759 | 2006 |
| Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical … HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 1741 | 2008 |
| Integrative clinical genomics of advanced prostate cancer D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ... Cell 161 (5), 1215-1228, 2015 | 1532 | 2015 |
| Cancer nanomedicine: progress, challenges and opportunities J Shi, PW Kantoff, R Wooster, OC Farokhzad Nature Reviews Cancer 17 (1), 20, 2017 | 1389 | 2017 |
| The genomic complexity of primary human prostate cancer MF Berger, MS Lawrence, F Demichelis, Y Drier, K Cibulskis, ... Nature 470 (7333), 214, 2011 | 1104 | 2011 |
| Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer CE Barbieri, SC Baca, MS Lawrence, F Demichelis, M Blattner, ... Nature genetics 44 (6), 685, 2012 | 1084 | 2012 |
| Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study PW Kantoff, S Halabi, M Conaway, J Picus, J Kirshner, V Hars, D Trump, ... Journal of Clinical Oncology 17 (8), 2506-2513, 1999 | 1058 | 1999 |
| The CAG repeat within the androgen receptor gene and its relationship to prostate cancer E Giovannucci, MJ Stampfer, K Krithivas, M Brown, A Brufsky, J Talcott, ... Proceedings of the National Academy of Sciences 94 (7), 3320-3323, 1997 | 957 | 1997 |
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ... Journal of Clinical Oncology 28 (7), 1099, 2010 | 954 | 2010 |
| Quantum dot− aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer V Bagalkot, L Zhang, E Levy-Nissenbaum, S Jon, PW Kantoff, R Langer, ... Nano letters 7 (10), 3065-3070, 2007 | 918 | 2007 |
| Early detection of prostate cancer: AUA Guideline HB Carter, PC Albertsen, MJ Barry, R Etzioni, SJ Freedland, KL Greene, ... The Journal of urology 190 (2), 419-426, 2013 | 909 | 2013 |
| Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile J Hrkach, D Von Hoff, MM Ali, E Andrianova, J Auer, T Campbell, ... Science translational medicine 4 (128), 128ra39-128ra39, 2012 | 855 | 2012 |
| 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial AV D'Amico, J Manola, M Loffredo, AA Renshaw, A DellaCroce, ... Jama 292 (7), 821-827, 2004 | 842 | 2004 |
| Punctuated evolution of prostate cancer genomes SC Baca, D Prandi, MS Lawrence, JM Mosquera, A Romanel, Y Drier, ... Cell 153 (3), 666-677, 2013 | 810 | 2013 |
| Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer Q Wang, W Li, Y Zhang, X Yuan, K Xu, J Yu, Z Chen, R Beroukhim, ... Cell 138 (2), 245-256, 2009 | 792 | 2009 |
| Prostate cancer J Mohler, RR Bahnson, B Boston, JE Busby, A D'Amico, JA Eastham, ... Journal of the National Comprehensive Cancer Network 8 (2), 162-200, 2010 | 759 | 2010 |
| Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer MR Smith, FJ McGovern, AL Zietman, MA Fallon, DL Hayden, ... New England Journal of Medicine 345 (13), 948-955, 2001 | 758 | 2001 |
| TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort F Demichelis, K Fall, S Perner, O Andrén, F Schmidt, SR Setlur, ... Oncogene 26 (31), 4596, 2007 | 695 | 2007 |
